Karyopharm to Announce Q1 2024 Financial Results on May 8, 2024

Karyopharm Therapeutics Inc., a pharmaceutical company known for its innovative cancer treatments, announced that it will release its first quarter 2024 financial results on Wednesday, May 8, 2024. The company's management team is scheduled to host a conference call and audio webcast on the same day at 8:00 a.m. ET to discuss the financial results alongside other company updates.

To participate in the conference call, interested parties should dial (800) 836-8184 for local access or (646) 357-8785 for international access at least 10 minutes before the scheduled start time. Participants should request to join the Karyopharm Therapeutics call. Additionally, a live audio webcast of the call, accompanied by slides, will be accessible through the "Events & Presentations" section of the Investor section on the company’s website. For those unable to attend the live event, an archived webcast will be available on the company’s website approximately two hours following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc., listed on Nasdaq under the ticker symbol KPTI, is a commercial-stage pharmaceutical firm dedicated to developing groundbreaking cancer therapies. The company has positioned itself as an industry leader in the development of oral compounds that address nuclear export dysregulation, a key mechanism in the development of cancer.

The company's flagship product, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor and the first of its kind. It has been approved for use in the United States and is marketed for three oncology indications. The compound has also received regulatory approval in various other countries and regions, including Europe, the United Kingdom (where it is marketed as NEXPOVIO®), and China.

Karyopharm's current product pipeline is focused on several types of cancers with significant unmet medical needs. These include multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). The company is committed to enhancing the lives of cancer patients through innovative treatments and a deep understanding of the science behind oncogenesis.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!